Dr. Reddy's Laboratories has informed stock exchanges about a significant development regarding its strategic collaboration with Immunet for the development of Eftilagimod Alfa, a potential cancer treatment. The pharmaceutical company disclosed that its licensing partner has announced the discontinuation of a critical Phase III clinical trial following safety and efficacy concerns.

Trial Discontinuation Details

Immunet announced on March 13, 2026, that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study has recommended discontinuing the trial. The study was evaluating Eftilagimod alfa in patients with first-line non-small cell lung cancer. This recommendation followed a planned interim futility analysis conducted in accordance with the established study protocol.

Strategic Partnership Background

The collaboration stems from a strategic licensing agreement between Dr. Reddy's Laboratories SA, a wholly-owned subsidiary, and Immunet SAS. Under this agreement announced on December 8, 2025, Dr. Reddy's obtained exclusive rights to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. Immunet Limited trades on both ASX (IMM) and NASDAQ (IMMP) exchanges.

Study Wind-Down Process

Following the IDMC's recommendation, Immunet will halt enrollment in the study immediately. The company has committed to implementing an orderly wind-down process that includes:

• Appropriate patient follow-up procedures
• Systematic site close-out activities
• Compliance with regulatory and ethical obligations
• Comprehensive review of available data

Immunet has indicated it will undertake a thorough analysis of the trial results to better understand the findings and determine appropriate next steps for the Eftilagimod Alpha program.

Financial Impact Assessment

Dr. Reddy's SA has confirmed that it has made only the upfront payment to Immunet to date and continues to engage with the partner regarding the appropriate way forward. The company noted that Immunet remains focused on advancing its pipeline of innovative therapies, including Eftilagimod Alpha, despite this setback.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency with stakeholders about material developments affecting the company's strategic partnerships and drug development pipeline.

Source: None/Company/INE089A01031/7e6b119a-792b-4a92-bffe-d3fe32fdcf56.pdf

Dr. Reddy's Laboratories has announced the opening of a special window for re-lodgement of transfer requests for physical shares through a newspaper advertisement published on March 12, 2026. The pharmaceutical company has taken this step to facilitate shareholders holding physical share certificates who need to complete their transfer processes.

Regulatory Compliance and Communication

The company published the advertisement in two prominent newspapers - Business Standard and Nava Telangana - in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to make certain disclosures through newspaper publications to ensure transparency and proper communication with stakeholders.

Stock Exchange Notification

Dr. Reddy's Laboratories formally communicated this development to both major stock exchanges where its shares are listed. The company sent official notifications to the National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) and BSE Limited (Scrip Code: 500124), providing copies of the newspaper advertisements as required under regulatory guidelines.

Corporate Communication Details

The official communication was signed by K Randhir Singh, who holds the positions of Company Secretary, Compliance Officer & Head-CSR at Dr. Reddy's Laboratories. The digital signature was applied on March 12, 2026, at 21:12:52 +05'30', ensuring the authenticity and timing of the corporate disclosure.

Company Information

Dr. Reddy's Laboratories Ltd. is headquartered at 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500 034, Telangana, India. The company operates under CIN: L85195TG1984PLC004507 and maintains its corporate website at www.drreddys.com . This special window initiative demonstrates the company's commitment to facilitating smooth share transfer processes for its physical shareholders while maintaining full regulatory compliance.